

Glutamatergic Modulators: The Future of Treating Mood

Harvard Review of Psychiatry

18, 293-303

DOI: [10.3109/10673229.2010.511059](https://doi.org/10.3109/10673229.2010.511059)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Late-life depression and Alzheimer's disease: The glutamatergic system inside of this mirror relationship. <i>Brain Research Reviews</i> , 2011, 67, 344-355.	9.1	34
2	Role of the mTOR signaling pathway in the rapid antidepressant action of ketamine. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 33-36.	1.4	41
3	Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. <i>Neurochemistry International</i> , 2011, 59, 896-905.	1.9	61
4	Cognitive dysfunction in depression: Neurocircuitry and new therapeutic strategies. <i>Neurobiology of Learning and Memory</i> , 2011, 96, 553-563.	1.0	264
5	Social Isolation-Induced Aggression Potentiates Anxiety and Depressive-Like Behavior in Male Mice Subjected to Unpredictable Chronic Mild Stress. <i>PLoS ONE</i> , 2011, 6, e20955.	1.1	88
6	Ketamine Influences CLOCK:BMAL1 Function Leading to Altered Circadian Gene Expression. <i>PLoS ONE</i> , 2011, 6, e23982.	1.1	59
7	Potentiation of μ -opioid receptor-mediated signaling by ketamine. <i>Journal of Neurochemistry</i> , 2011, 119, 294-302.	2.1	94
8	Effects of chronic treatment with fluoxetine on receptor-stimulated increase of $[Ca^{2+}]_i$ in astrocytes mimic those of acute inhibition of TRPC1 channel activity. <i>Cell Calcium</i> , 2011, 50, 42-53.	1.1	31
9	Effects of Venlafaxine and Escitalopram Treatments on NMDA Receptors in the Rat Depression Model. <i>Journal of Membrane Biology</i> , 2011, 242, 145-151.	1.0	18
10	A Role for the PKC Signaling System in the Pathophysiology and Treatment of Mood Disorders: Involvement of a Functional Imbalance?. <i>Molecular Neurobiology</i> , 2011, 44, 407-419.	1.9	31
11	<i>In vivo</i> and <i>ex vivo</i> evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia. <i>NMR in Biomedicine</i> , 2011, 24, 1235-1242.	1.6	59
12	NMDA Receptor Signaling in Oligodendrocyte Progenitors Is Not Required for Oligodendrogenesis and Myelination. <i>Journal of Neuroscience</i> , 2011, 31, 12650-12662.	1.7	130
13	Ionotropic glutamate receptor mRNA editing in the prefrontal cortex: no alterations in schizophrenia or bipolar disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2012, 37, 267-272.	1.4	9
14	Tramadol Pretreatment Enhances Ketamine-Induced Antidepressant Effects and Increases Mammalian Target of Rapamycin in Rat Hippocampus and Prefrontal Cortex. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-6.	3.0	25
15	Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study. <i>Neuropsychopharmacology</i> , 2012, 37, 1526-1533.	2.8	262
16	Mood and Pain Responses to Repeat Dose Intramuscular Ketamine in a Depressed Patient with Advanced Cancer. <i>Journal of Palliative Medicine</i> , 2012, 15, 400-403.	0.6	42
17	Depression: an inflammatory illness?: Figure 1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 495-502.	0.9	339
18	Molecular adaptation to chronic antidepressant treatment: evidence for a more rapid response to the novel β_2 -adrenoceptor antagonist/5-HT-noradrenaline reuptake inhibitor (SNRI), S35966, compared to the SNRI, venlafaxine. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 617-629.	1.0	14

#	ARTICLE	IF	CITATIONS
20	Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. <i>Bipolar Disorders</i> , 2012, 14, 880-887.	1.1	61
21	Evidence-based options for treatment-resistant adult bipolar disorder patients. <i>Bipolar Disorders</i> , 2012, 14, 573-584.	1.1	48
22	Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder. <i>Annals of Pharmacotherapy</i> , 2012, 46, 117-123.	0.9	44
23	Emerging drugs for major depressive disorder. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 105-126.	1.0	74
24	Ketamina. <i>EMC - Anestesia-Reanimación</i> , 2012, 38, 1-13.	0.1	0
26	An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. <i>Medical Hypotheses</i> , 2012, 78, 693-702.	0.8	43
27	Low-dose neonatal domoic acid causes persistent changes in behavioural and molecular indicators of stress response in rats. <i>Behavioural Brain Research</i> , 2012, 230, 409-417.	1.2	21
28	Targeting the Glutamatergic System to Treat Major Depressive Disorder. <i>Drugs</i> , 2012, 72, 1313-1333.	4.9	181
29	Rapid-acting antidepressant strategies: mechanisms of action. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 695-713.	1.0	68
30	CHAPTER 5. Discovery and Clinical Data for a Novel AMPA Receptor Positive Modulator. <i>RSC Drug Discovery Series</i> , 2012, , 99-122.	0.2	0
31	CHAPTER 7. The Neurobiology of Depression and Anxiety: How Do We Change from Models of Drug Efficacy to Understanding Mood and Anxiety Disorders?. <i>RSC Drug Discovery Series</i> , 2012, , 159-183.	0.2	2
32	Blockade of α_2 -adrenoceptors induces Arc gene expression in rat brain in a glutamate receptor-dependent manner: A combined qPCR, in situ hybridisation and immunocytochemistry study. <i>Neuropharmacology</i> , 2012, 63, 992-1001.	2.0	6
33	Calcium-Dependent Networks in Dopamine-Glutamate Interaction: The Role of Postsynaptic Scaffolding Proteins. <i>Molecular Neurobiology</i> , 2012, 46, 275-296.	1.9	50
34	Novel Insights into Depression and Antidepressants: A Synergy Between Synaptogenesis and Neurogenesis?. <i>Current Topics in Behavioral Neurosciences</i> , 2012, 15, 243-291.	0.8	40
35	Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder. <i>Brain Research</i> , 2012, 1459, 91-99.	1.1	17
36	Sub-chronic dietary tryptophan depletion – An animal model of depression with improved face and good construct validity. <i>Journal of Psychiatric Research</i> , 2012, 46, 239-247.	1.5	30
37	Does conventional anti-bipolar and antidepressant drug therapy reduce NMDA-mediated neuronal excitation by downregulating astrocytic GluK2 function?. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 712-725.	1.3	19
38	Roles of glutamate signaling in preclinical and/or mechanistic models of depression. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 688-704.	1.3	89

#	ARTICLE	IF	CITATIONS
39	Depressive-like behavior in adrenocorticotrophic hormone-treated rats blocked by memantine. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 102, 329-334.	1.3	23
40	Antibodies to the glutamate receptor in mania. <i>Bipolar Disorders</i> , 2012, 14, 547-553.	1.1	47
41	Dysfunctional astrocytic regulation of glutamate transmission in a rat model of depression. <i>Molecular Psychiatry</i> , 2013, 18, 582-594.	4.1	94
42	Chemotherapy in Psychiatry. , 2013, , .		144
43	Repeated administration of imipramine modifies GABAergic transmission in rat frontal cortex. <i>Journal of Neural Transmission</i> , 2013, 120, 711-719.	1.4	4
44	Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: Involvement of nitric oxide. <i>European Neuropsychopharmacology</i> , 2013, 23, 1769-1778.	0.3	50
45	Antidepressant-like effect of α -tocopherol in a mouse model of depressive-like behavior induced by TNF- α . <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 46, 48-57.	2.5	53
46	Inhibition of Glycine Transporter-1 as a Novel Mechanism for the Treatment of Depression. <i>Biological Psychiatry</i> , 2013, 74, 734-741.	0.7	124
47	Innovative solutions to novel drug development in mental health. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2438-2444.	2.9	102
48	Depressies bij multiple sclerose. <i>Tijdschrift Voor Neuropsychiatrie En Gedragsneurologie</i> , 2013, 1, 12-21.	0.1	4
49	Bcl-2 rs956572 Polymorphism is Associated with Increased Anterior Cingulate Cortical Glutamate in Euthymic Bipolar I Disorder. <i>Neuropsychopharmacology</i> , 2013, 38, 468-475.	2.8	65
50	Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. <i>Pharmacogenomics</i> , 2013, 14, 277-288.	0.6	43
51	A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2013, 147, 416-420.	2.0	52
52	Impact of early-life stress, on group III mGlu receptor levels in the rat hippocampus: Effects of ketamine, electroconvulsive shock therapy and fluoxetine treatment. <i>Neuropharmacology</i> , 2013, 66, 236-241.	2.0	34
53	Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants. , 2013, , 343-411.		3
54	Antidepressants act directly on astrocytes: Evidences and functional consequences. <i>European Neuropsychopharmacology</i> , 2013, 23, 171-185.	0.3	111
55	Ketamine as a Fast Acting Antidepressant: Current Knowledge and Open Questions. <i>CNS Neuroscience and Therapeutics</i> , 2013, 19, 428-436.	1.9	63
56	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 367-377.	1.8	177

#	ARTICLE	IF	CITATIONS
57	Glutamate system as target for development of novel antidepressants. <i>CNS Spectrums</i> , 2013, 18, 188-198.	0.7	24
58	microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1885-1892.	1.0	98
59	Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression. <i>Progress in Neurobiology</i> , 2013, 100, 15-29.	2.8	169
60	Mood-Stabilizing Agents. , 2013, , 89-154.		1
61	Unmet needs in psychiatry and emerging novel pharmacological agents. <i>Journal of Microbiology and Biotechnology</i> , 2013, 23, 199-204.	0.9	1
62	Lithium's role in neural plasticity and its implications for mood disorders. <i>Acta Psychiatrica Scandinavica</i> , 2013, 128, 347-361.	2.2	45
63	Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic Implications. <i>International Journal of Biological Sciences</i> , 2013, 9, 728-742.	2.6	69
64	Long-Lasting Antidepressant Action of Ketamine, but Not Glycogen Synthase Kinase-3 Inhibitor SB216763, in the Chronic Mild Stress Model of Mice. <i>PLoS ONE</i> , 2013, 8, e56053.	1.1	94
65	A comment on Fond and colleagues's™ systematic review and meta-analysis of ketamine in the treatment of depressive disorders (<i>Psychopharmacology</i> 2014; Jul 20 [Epub ahead of print]). <i>Psychopharmacology</i> , 2014, 231, 3907-3908.	1.5	4
66	Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach. <i>World Journal of Biological Psychiatry</i> , 2014, 15, 84-95.	1.3	52
67	MRS of Psychiatric Disorders. , 2014, , 222-228.		2
68	Molecular mechanisms linking neuroinflammation and neurodegeneration in MS. <i>Experimental Neurology</i> , 2014, 262, 8-17.	2.0	136
69	R (âˆš)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 116, 137-141.	1.3	275
70	MAPK signaling correlates with the antidepressant effects of ketamine. <i>Journal of Psychiatric Research</i> , 2014, 55, 15-21.	1.5	86
71	A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. <i>Journal of Affective Disorders</i> , 2014, 156, 24-35.	2.0	156
72	Toward a Biosignature for Suicide. <i>American Journal of Psychiatry</i> , 2014, 171, 1259-1277.	4.0	238
73	Guanosine prevents behavioral alterations in the forced swimming test and hippocampal oxidative damage induced by acute restraint stress. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 127, 7-14.	1.3	53
75	The utility of the combination of dextromethorphan and quinidine in the treatment of bipolar II and bipolar NOS. <i>Journal of Affective Disorders</i> , 2014, 167, 333-335.	2.0	41

#	ARTICLE	IF	CITATIONS
76	Epigenetic mechanisms in mood disorders: Targeting neuroplasticity. <i>Neuroscience</i> , 2014, 264, 112-130.	1.1	54
77	Long-term NMDAR antagonism correlates reduced astrocytic glutamate uptake with anxiety-like phenotype. <i>Frontiers in Cellular Neuroscience</i> , 2015, 09, 219.	1.8	16
78	Translational Research in Bipolar Disorders. <i>Neural Plasticity</i> , 2015, 2015, 1-3.	1.0	2
79	Riluzole Stimulates BDNF Release from Human Platelets. <i>BioMed Research International</i> , 2015, 2015, 1-6.	0.9	19
80	Bipolar disorder and antibodies against the N-methyl-d-aspartate receptor: A gate to the involvement of autoimmunity in the pathophysiology of bipolar illness. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 403-412.	2.9	24
81	The medial forebrain bundle as a deep brain stimulation target for treatment resistant depression: A review of published data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 58, 59-70.	2.5	39
82	Anxiolytic effects of ketamine in animal models of posttraumatic stress disorder. <i>Psychopharmacology</i> , 2015, 232, 663-672.	1.5	77
83	Antidepressant Effects of TrkB Ligands on Depression-Like Behavior and Dendritic Changes in Mice After Inflammation. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	1.0	193
84	Dentate gyrus-CA3 glutamate release/NMDA transmission mediates behavioral despair and antidepressant-like responses to leptin. <i>Molecular Psychiatry</i> , 2015, 20, 509-519.	4.1	40
85	Absence of system xc ⁻ in mice decreases anxiety and depressive-like behavior without affecting sensorimotor function or spatial vision. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 59, 49-58.	2.5	28
86	Differences in extracellular glutamate levels in striatum of rats with high and low exploratory activity. <i>Pharmacological Reports</i> , 2015, 67, 858-865.	1.5	6
87	Involvement of AMPA receptors in the antidepressant-like effects of dextromethorphan in mice. <i>Behavioural Brain Research</i> , 2015, 295, 26-34.	1.2	37
88	Emergent treatments based on the pathophysiology of bipolar disorder: A selective review. <i>Asian Journal of Psychiatry</i> , 2015, 18, 15-21.	0.9	10
89	Inhibition of in vivo [3H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. <i>European Journal of Pharmacology</i> , 2015, 766, 1-8.	1.7	18
90	A Longitudinal (6-week) 3T 1H-MRS Study on the Effects of Lithium Treatment on Anterior Cingulate Cortex Metabolites in Bipolar Depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 2311-2317.	0.3	50
91	Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. <i>Psychopharmacology</i> , 2015, 232, 4325-4335.	1.5	150
92	Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder. <i>Molecular Psychiatry</i> , 2015, 20, 48-55.	4.1	157
93	Behavioural screening of zebrafish using neuroactive traditional Chinese medicine prescriptions and biological targets. <i>Scientific Reports</i> , 2014, 4, 5311.	1.6	19

#	ARTICLE	IF	CITATIONS
94	Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness?. <i>World Journal of Psychiatry</i> , 2016, 6, 283.	1.3	161
95	Dextromethorphan and Dextrorphan as Heuristic Rapid-Acting, Conventional, and Treatment-Resistant Antidepressants, with Substance Abuse Considerations. , 2016, , 707-717.		1
96	Molecular Mechanisms of Depression. , 2016, , 143-178.		7
97	Pushing the threshold: How NMDAR antagonists induce homeostasis through protein synthesis to remedy depression. <i>Brain Research</i> , 2016, 1647, 94-104.	1.1	11
98	New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders. <i>Current Psychiatry Reports</i> , 2016, 18, 64.	2.1	10
99	Abnormality in glutamineâ€“glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. <i>Translational Psychiatry</i> , 2016, 6, e744-e744.	2.4	69
100	A microdialysis and enzymatic reactor sensing procedure for the simultaneous registration of online glutamate measurements at high temporal resolution during epileptiform activity. <i>Journal of Neurochemistry</i> , 2016, 139, 886-896.	2.1	8
101	Ultimate Translation. <i>Advances in Pharmacology</i> , 2016, 76, 257-309.	1.2	7
102	All Roads Lead to the miRNome: miRNAs Have a Central Role in the Molecular Pathophysiology of Psychiatric Disorders. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 1029-1044.	4.0	60
103	Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 31, 173-198.	0.8	99
104	Novel Targets for Drug Treatment in Psychiatry. , 2016, , 601-654.		0
105	Reliability of 7T ¹ H-MRS measured human prefrontal cortex glutamate, glutamine, and glutathione signals using an adapted echo time optimized PRESS sequence: A between- and within-sessions investigation. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 43, 88-98.	1.9	35
106	Oral ketamine for the treatment of pain and treatment-resistant depression. <i>British Journal of Psychiatry</i> , 2016, 208, 108-113.	1.7	57
107	Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2016, 75, 24-30.	1.5	44
108	Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder. <i>Neuroscience</i> , 2016, 316, 209-220.	1.1	180
109	New targets for rapid antidepressant action. <i>Progress in Neurobiology</i> , 2017, 152, 21-37.	2.8	118
110	Evidence for the involvement of heme oxygenase-1 in the antidepressant-like effect of zinc. <i>Pharmacological Reports</i> , 2017, 69, 497-503.	1.5	13
111	Glial GLT-1 blockade in infralimbic cortex as a new strategy to evoke rapid antidepressant-like effects in rats. <i>Translational Psychiatry</i> , 2017, 7, e1038-e1038.	2.4	57

#	ARTICLE	IF	CITATIONS
112	Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 77, 232-236.	2.9	91
113	A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 355-358.	0.7	28
114	Lithium Response Variability (Pharmacogenomics Studies). , 2017, , 141-155.		0
115	Role of the Astroglial Glutamate Exchanger xCT in Ventral Hippocampus in Resilience to Stress. <i>Neuron</i> , 2017, 96, 402-413.e5.	3.8	98
116	Short- and long-term antidepressant effects of ketamine in a rat chronic unpredictable stress model. <i>Brain and Behavior</i> , 2017, 7, e00749.	1.0	44
117	4-phenylselenyl-7-chloroquinoline, a novel multitarget compound with anxiolytic activity: Contribution of the glutamatergic system. <i>Journal of Psychiatric Research</i> , 2017, 84, 191-199.	1.5	50
118	Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. <i>Neuropsychopharmacology</i> , 2017, 42, 193-215.	2.8	343
119	Effects of systemic glutamatergic manipulations on conditioned eyeblink responses and hyperarousal in a rabbit model of post-traumatic stress disorder. <i>Behavioural Pharmacology</i> , 2017, 28, 565-577.	0.8	5
120	Temperament and Character Inventory in Bipolar Disorder versus Healthy Controls and Modulatory Effects of 3 Key Functional Gene Variants. <i>Neuropsychobiology</i> , 2017, 76, 209-221.	0.9	11
121	Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 1627-1632.	1.0	28
122	Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 629-634.	1.5	50
123	Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions. <i>Journal of Affective Disorders</i> , 2018, 236, 291-297.	2.0	44
124	Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 82, 332-338.	2.5	20
125	Engaging homeostatic plasticity to treat depression. <i>Molecular Psychiatry</i> , 2018, 23, 26-35.	4.1	39
126	Ketamine normalizes brain activity during emotionally valenced attentional processing in depression. <i>NeuroImage: Clinical</i> , 2018, 20, 92-101.	1.4	51
127	Monosodium glutamate influences depressive behavior of two age groups of mice in forced swimming test: Vitamin B6 could remedy the situation. <i>Personalized Medicine in Psychiatry</i> , 2019, 15-16, 28-32.	0.1	3
128	Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. <i>CNS Spectrums</i> , 2019, 24, 461-466.	0.7	34
129	The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants?. <i>Current Therapeutic Research</i> , 2019, 91, 25-32.	0.5	9

#	ARTICLE	IF	CITATIONS
130	Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies. , 2019, 199, 58-90.		126
131	The molecular neurobiology of chronic pain-induced depression. <i>Cell and Tissue Research</i> , 2019, 377, 21-43.	1.5	88
132	Recent Studies on Anti-Depressant Bioactive Substances in Selected Species from the Genera <i>Hemerocallis</i> and <i>Gladiolus</i> : A Systematic Review. <i>Pharmaceuticals</i> , 2019, 12, 172.	1.7	27
133	Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task. <i>European Neuropsychopharmacology</i> , 2019, 29, 222-234.	0.3	22
134	SIRT1 in forebrain excitatory neurons produces sexually dimorphic effects on depression-related behaviors and modulates neuronal excitability and synaptic transmission in the medial prefrontal cortex. <i>Molecular Psychiatry</i> , 2020, 25, 1094-1111.	4.1	80
135	Lactate measurement by neurochemical profiling in the dorsolateral prefrontal cortex at 7T: accuracy, precision, and relaxation times. <i>Magnetic Resonance in Medicine</i> , 2020, 83, 1895-1908.	1.9	10
136	The involvement of PI3K/Akt/mTOR/GSK3 ^β signaling pathways in the antidepressant-like effect of AZD6765. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 198, 173020.	1.3	27
137	Proton Exchange Magnetic Resonance Imaging: Current and Future Applications in Psychiatric Research. <i>Frontiers in Psychiatry</i> , 2020, 11, 532606.	1.3	6
138	Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder. <i>Frontiers in Psychiatry</i> , 2020, 11, 590095.	1.3	16
139	Glutamatergic Correlates of Bipolar Symptoms in Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2020, 30, 599-605.	0.7	3
140	Pharmacological Treatment of Bipolar Depression: What are the Current and Emerging Options?. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1459-1472.	1.0	9
141	Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis. <i>Archives of Toxicology</i> , 2020, 94, 2829-2845.	1.9	7
142	Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression. <i>Chemico-Biological Interactions</i> , 2020, 319, 109006.	1.7	4
143	Blood glutamate scavenging as a novel glutamate-based therapeutic approach for post-stroke depression. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532090395.	1.2	13
144	Organ-level protein networks as a reference for the host effects of the microbiome. <i>Genome Research</i> , 2020, 30, 276-286.	2.4	6
145	Efficacy and safety of riluzole for depressive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials. <i>Psychiatry Research</i> , 2020, 284, 112750.	1.7	8
146	Involvement of glutamate and serotonin transmitter systems in male sex determination in <i>Daphnia pulex</i> . <i>Journal of Insect Physiology</i> , 2020, 121, 104015.	0.9	6
147	Differential effects of traxoprodil and S-ketamine on quantitative EEG and auditory event-related potentials as translational biomarkers in preclinical trials in rats and mice. <i>Neuropharmacology</i> , 2020, 171, 108072.	2.0	4

#	ARTICLE	IF	CITATIONS
148	Impact of SAfinamide on Depressive Symptoms in Parkinsonâ€™s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study. <i>Brain Sciences</i> , 2021, 11, 232.	1.1	22
149	Pharmacologie de la kÃ©tamine. <i>Douleur Et Analgesie</i> , 2021, 34, 3-15.	0.2	1
150	A study of tools for differential co-expression analysis for RNA-Seq data. <i>Informatics in Medicine Unlocked</i> , 2021, 26, 100740.	1.9	4
151	Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression. <i>Pharmacological Research</i> , 2021, 171, 105761.	3.1	31
152	<i>Affektive StÃ¶rungen.</i> , 2012, , 421-512.		1
153	The role of leptin in central nervous system diseases. <i>NeuroReport</i> , 2016, 27, 350-355.	0.6	20
154	Next-generation strategies in animal model research to translate preclinical discoveries into better treatments for circuit-centered psychiatric dimensions. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, S75-S76.	0.9	1
155	Antidepressant Effects of Ketamine on Depression-like Behavior in Juvenile Mice after Neonatal Dexamethasone Exposure. <i>Clinical Psychopharmacology and Neuroscience</i> , 2014, 12, 124-127.	0.9	13
156	Therapeutic Modalities for Treatment Resistant Depression: Focus on Vagal Nerve Stimulation and Ketamine. <i>Clinical Psychopharmacology and Neuroscience</i> , 2014, 12, 83-93.	0.9	29
157	AMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants. <i>Contemporary Clinical Neuroscience</i> , 2021, , 85-109.	0.3	0
158	<i>Development of Brain Monoaminergic Systems.</i> , 2011, , 130-151.		0
159	Beta-Arrestins in Depression: A Molecular Switch from Signal Desensitization to Alternative Intracellular Adaptor Functions. , 2011, , 404-423.		1
160	<i>Vraies et fausses innovations en psychiatrie.</i> , 2012, , 125-143.		0
161	<i>Antidepressant-Antianxiety Agents.</i> , 2013, , 155-250.		0
162	<i>Future Directions in Psychopharmacology of Autism Spectrum Disorder.</i> , 2014, , 473-495.		0
163	Making Ketamine Work in the Long Run. <i>International Journal of Transpersonal Studies</i> , 2014, 33, 141-150.	0.2	1
164	<i>Affektive StÃ¶rungen.</i> , 2015, , 413-498.		0
165	<i>Bipolar Illness.</i> , 2016, , 53-78.		0

#	ARTICLE	IF	CITATIONS
166	Affektive Störungen. , 2019, , 363-444.e8.		1
168	Emerging role of microRNAs as novel targets of antidepressants. Asian Journal of Psychiatry, 2021, 66, 102906.	0.9	1
169	One century of healing currents into the brain from the scalp: From electroconvulsive therapy to repetitive transcranial magnetic stimulation for neuropsychiatric disorders. Clinical Neurophysiology, 2022, 133, 145-151.	0.7	7
170	Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. Neurological Sciences, 2022, 43, 3187-3193.	0.9	1
171	Embodied Value Theory. , 2022, , 11-35.		0
172	What Drugs Do in Different Spaces. , 2022, , 117-135.		0
173	Same Ills, Same Pills. , 2022, , 194-213.		0
174	Pharmaceutical Citizenship, Marketing, and the Global Monoculture of Health. , 2022, , 98-116.		0
175	Never Enough. , 2022, , 57-78.		0
176	Culture, Context, and Consensus. , 2022, , 156-174.		0
177	Failed Biocommensurations. , 2022, , 214-234.		0
179	Blood Glutamate Scavenging With Pyruvate as a Novel Preventative and Therapeutic Approach for Depressive-Like Behavior Following Traumatic Brain Injury in a Rat Model. Frontiers in Neuroscience, 2022, 16, 832478.	1.4	7
182	Acting through Other (Prescribing) Habits. , 2022, , 136-155.		0
183	Generic. , 2022, , 175-193.		0
184	Carnitine and Depression. Frontiers in Nutrition, 2022, 9, 853058.	1.6	9
185	Antidepressant activity of phytochemicals of Mangifera indica seeds assisted by integrated computational analysis. Metabolic Brain Disease, 2023, 38, 483-505.	1.4	2
186	Hierarchical Clustering of Multi-Study Depression Data Yields Four Symptom Clusters. , 2021, , .		0
188	Relative Value. , 2022, , 36-56.		0

#	ARTICLE	IF	CITATIONS
190	The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. Journal of Midwifery and Women's Health, 2022, 67, 373-383.	0.7	2
195	Adjunctive dopaminergic enhancement of esketamine in treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 119, 110603.	2.5	1
196	Second messengers and their importance for novel drug treatments of patients with bipolar disorder. International Review of Psychiatry, 2022, 34, 736-752.	1.4	3
198	Discovery of a Series of Substituted 1 <i>H</i> -((1,2,3-Triazol-4-yl)methoxy)pyrimidines as Brain Penetrants and Potent GluN2B-Selective Negative Allosteric Modulators. Journal of Medicinal Chemistry, 2023, 66, 2877-2892.	2.9	1
199	The Glutamatergic System in Treatment-Resistant Depression and Comparative Effectiveness of Ketamine and Esketamine: Role of Inflammation?. Advances in Experimental Medicine and Biology, 2023, , 487-512.	0.8	4
203	The neuropsychopharmacology of acetyl-L-carnitine (LAC): basic, translational and therapeutic implications. Discover Mental Health, 2024, 4, .	1.0	0